Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study
| Autor: | Chris Fox, George M. Savva, Robert Howard, Nicholas Steel, Clive Ballard, Ian Maidment, Yoon K. Loke, Kathryn Richardson, Penelope J Boyd, Antony Arthur, Clare F Aldus |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Sleep Wake Disorders medicine.medical_specialty Piperazines Cohort Studies Benzodiazepines 03 medical and health sciences 0302 clinical medicine Internal medicine Acetamides medicine Humans Dementia Sleep initiation and maintenance disorders 030212 general & internal medicine Adverse effect Stroke Accidental falls Aged 80 and over Zopiclone Sleep disorder Hip fracture business.industry Hazard ratio General Medicine medicine.disease Confidence interval Zolpidem Pyrimidines Hip fractures Female Alzheimer disease business Azabicyclo Compounds 030217 neurology & neurosurgery Research Article medicine.drug |
| Zdroj: | BMC Medicine |
| ISSN: | 1741-7015 |
| Popis: | BackgroundSleep disturbance is common in dementia and often treated with Z-drugs (zopiclone, zaleplon, and zolpidem). While some observational studies suggest that Z-drugs are associated with adverse events such as falls and fracture risks in older people, this has not been studied in dementia.MethodsWe used data from 27,090 patients diagnosed with dementia between January 2000 and March 2016 from the Clinical Practice Research Datalink linked to Hospital Episodes Statistics data in England. We compared adverse events for 3532 patients newly prescribed Z-drugs by time-varying dosage to (1) 1833 non-sedative-users with sleep disturbance; (2) 10,214 non-sedative-users with proximal GP consultation matched on age, sex, and antipsychotic use; and (3) 5172 patients newly prescribed benzodiazepines. We defined higher dose Z-drugs and benzodiazepines as prescriptions equivalent to ≥ 7.5 mg zopiclone or > 5 mg diazepam daily. Cox regression was used to estimate hazard ratios (HRs) for incident fracture, hip fracture, fall, mortality, acute bacterial infection, ischaemic stroke/transient ischaemic attack, and venous thromboembolism over a 2-year follow-up, adjusted for demographic- and health-related covariates.ResultsThe mean (SD) age of patients was 83 (7.7) years, and 16,802 (62%) were women. Of 3532 patients prescribed Z-drugs, 584 (17%) were initiated at higher doses. For patients prescribed higher dose Z-drugs relative to non-users with sleep disturbance, the HRs (95% confidence interval) for fractures, hip fractures, falls, and ischaemic stroke were 1.67 (1.13–2.46), 1.96 (1.16–3.31), 1.33 (1.06–1.66), and 1.88 (1.14–3.10), respectively. We observed similar associations when compared to non-sedative-users with proximal GP consultation. Minimal or inconsistent excess risks were observed at ≤ 3.75 mg zopiclone or equivalent daily, and for mortality, infection, and venous thromboembolism. We observed no differences in adverse events for Z-drugs compared to benzodiazepines, except lower mortality rates with Z-drugs (HR [95% confidence interval] of 0.73 [0.64–0.83]).ConclusionsHigher dose Z-drug use in dementia is associated with increased fracture and stroke risks, similar or greater to that for higher dose benzodiazepines. Higher dose Z-drugs should be avoided, if possible, in people living with dementia, and non-pharmacological alternatives preferentially considered. Prescriptions for higher dose Z-drugs in dementia should be regularly reviewed.Trial registrationENCePP e-register of studies,EUPAS18006 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink